| Bolling, Steven |
NCT03793465: Pilot-Tart Cherry, Mitral Transcriptome, and POAF Incidence |
|
|
| Active, not recruiting | 1/2 | 50 | US | tart cherry concentrate | University of Michigan, Cherry Marketing Institute, Dewitt MI (USA) | Post-operative Atrial Fibrillation (POAF) | 01/26 | 01/26 | | |
NCT05991700: Anthocyanin-Rich Table Grape Powder for Prophylaxis of Post-Operative Atrial Fibrillation |
|
|
| Not yet recruiting | 1/2 | 70 | US | Freeze-Dried California Table Grape, Placebo | University of Michigan, California Table Grape Commission | Post-operative Atrial Fibrillation (POAF) | 07/26 | 07/26 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MitraClip™ device implantation, Mitral Valve Repair Surgery | Abbott Medical Devices | Mitral Valve Regurgitation | 04/26 | 04/34 | | |
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. |
|
|
| Recruiting | N/A | 1056 | Europe, Canada, US | Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) | Medtronic Cardiovascular | Mitral Valve Regurgitation | 10/26 | 09/36 | | |
| McCarthy, Patrick J |
| Completed | N/A | 39 | US | Surgical Ablation | AtriCure, Inc. | Atrial Fibrillation, Atrial Flutter | 03/23 | 12/23 | | |
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment |
|
|
| Active, not recruiting | N/A | 150 | US | AtriCure CryoICE & AtriClip LAA Exclusion | AtriCure, Inc. | Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 06/24 | 06/26 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MitraClip™ device implantation, Mitral Valve Repair Surgery | Abbott Medical Devices | Mitral Valve Regurgitation | 04/26 | 04/34 | | |
| Recruiting | N/A | 6500 | Europe, Canada, US | AtriClip LAA Exclusion System | AtriCure, Inc., Population Health Research Institute | Ischemic Stroke, Systemic Embolism | 12/31 | 04/32 | | |
| Kanate, Abraham |
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage |
|
|
| Recruiting | 3 | 450 | US | DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine | Delta-Fly Pharma, Inc. | Leukemia, Myeloid, Acute | 12/22 | 12/22 | | |
NCT01203020: Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation |
|
|
| Completed | 2 | 22 | US | Busulfan, Busulfex, Fludarabine, Fludarabine Monophosphate, Fludara | West Virginia University | Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | 09/21 | 09/21 | | |
| Craig, Michael |
NCT01041703: Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
|
|
| Recruiting | 3 | 747 | US, RoW | clofarabine, cytarabine, daunorubicin hydrochloride, decitabine | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) | Leukemia | 02/19 | | | |
| Smith, Mark |
NCT04214834: Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS) |
|
|
| Active, not recruiting | 3 | 190 | US | Morphine, Methadone | Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Neonatal Opioid Withdrawal Syndrome | 01/24 | 06/26 | | |
NCT04114981: Single Fraction Stereotactic Radiosurgery Compared with Fractionated Stereotactic Radiosurgery in Treating Patients with Resected Metastatic Brain Disease |
|
|
| Active, not recruiting | 3 | 242 | Canada, US | Single Fraction Stereotactic Radiosurgery, Stereotactic Radiosurgery, Fractionated Stereotactic Radiosurgery, Quality-of-Life Assessment, Questionnaire Administration | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Metastatic Malignant Neoplasm in the Brain | 03/26 | 03/28 | | |
| Recruiting | N/A | 200 | US | Lumbar Interbody Fusion | 3Spine, MCRA | Lumbar Spine Degeneration | 05/24 | 08/26 | | |
| Carpenter, Jeffrey |
EVAS IDE, NCT01726257: Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System |
|
|
| Completed | N/A | 430 | Europe, US | Nellix System | Endologix | Abdominal Aortic Aneurysm (AAA) | 06/16 | 12/22 | | |
EVAS2, NCT03298477: IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study |
|
|
| Active, not recruiting | N/A | 98 | US | Nellix® System | Endologix | Abdominal Aortic Aneurysm Without Rupture | 06/22 | 08/25 | | |
| Rai, Ansaar |
PICASSO, NCT05611242: Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial |
|
|
| Recruiting | 3 | 404 | US | MT+CAS with IV-AP, Thrombectomy, MT+CAS with PO-AP, MT+CAT with PO-AP | Mercy Health Ohio | Acute Ischemic Stroke | 03/26 | 05/27 | | |
NCT05018650: A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX) |
|
|
| Active, not recruiting | N/A | 250 | US, RoW | Route 92 Medical Reperfusion System | Route 92 Medical, Inc. | Acute Ischemic Stroke | 06/24 | 06/24 | | |
MEMBRANE, NCT04816591: Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA |
|
|
| Active, not recruiting | N/A | 376 | US | Experimental: Interventional Cohort: Treatment Arm, Active Comparator: Interventional Cohort: Control Arm, Experimental: Observational Cohort: Treatment Arm, Active Comparator: Observational Cohort: Control Arm | Cerenovus, Part of DePuy Synthes Products, Inc. | Chronic Subdural Hematoma | 08/24 | 05/25 | | |
SPLENDID, NCT06386289: Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke |
|
|
| Not yet recruiting | N/A | 140 | US | Cereglide 92 | Cerenovus, Part of DePuy Synthes Products, Inc. | Acute Ischemic Stroke | 02/26 | 06/26 | | |
| Recruiting | N/A | 150 | US | Citadel Embolization Device | Stryker Neurovascular | Unruptured Wide-neck Aneurysms | 06/26 | 06/26 | | |
TESTED, NCT05911568: Treatment With Endovascular Intervention for STroke Patients With Existing Disability |
|
|
| Recruiting | N/A | 1060 | US | Endovascular Stroke Treatment, Medical Management | University of Cincinnati, Patient-Centered Outcomes Research Institute, University of California, Los Angeles, Icahn School of Medicine at Mount Sinai | Stroke, Stroke, Acute, Stroke, Ischemic | 01/28 | 04/28 | | |
| Recruiting | N/A | 40000 | Europe, Canada, Japan, US, RoW | Stroke/Thrombectomy/Aneurysm-specific surgical procedures | Medical University of South Carolina | Stroke, Thromboses, Intracranial, Aneurysm, Brain | 01/55 | 01/55 | | |
| Kar, Saibal |
| Active, not recruiting | N/A | 572 | Europe, Canada, US | TriClipTM Device | Abbott Medical Devices | Tricuspid Regurgitation | 11/22 | 04/29 | | |
NCT04029337: An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System |
|
|
| Recruiting | N/A | 30 | US | Transcatheter Mitral Valve Replacement | HighLife SAS | Mitral Regurgitation | 12/24 | 12/27 | | |
| Recruiting | N/A | 250 | Europe, US | reSept ASD Occluder | atHeart Medical | Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities | 12/26 | 12/30 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
| Enrolling by invitation | N/A | 1500 | US | Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet | Laminar, Inc., Cardiovascular Research Foundation, New York | Non-valvular Atrial Fibrillation, Stroke | 08/28 | 02/32 | | |
| Recruiting | N/A | 25 | US | CardioMech MVRS | CardioMech AS | Mitral Regurgitation | 12/25 | 12/30 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
NCT05565599: An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 45 | US | Left Atrial Appendage Closure | Laminar, Inc. | Non-valvular Atrial Fibrillation | 08/24 | 09/29 | | |
NCT05913908: EFS of the DUO System for Tricuspid Regurgitation |
|
|
| Recruiting | N/A | 15 | US | DUO Transcatheter Tricuspid Coaptation Valve System, DUO System | CroiValve Limited | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases | 12/25 | 10/29 | | |
NCT06212193: Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS) |
|
|
| Recruiting | N/A | 15 | US | Trillium™ | Innoventric LTD, Innoventric Inc. | Tricuspid Regurgitation, Tricuspid Regurgitation Functional | 08/25 | 08/30 | | |
| Active, not recruiting | N/A | 949 | US | WATCHMAN FLX Pro LAAC Device, Left Atrial Appendage Closure | Boston Scientific Corporation | Atrial Fibrillation, Bleeding, Stroke | 07/24 | 08/25 | | |
| Recruiting | N/A | 1857 | US | WATCHMAN FLX Pro LAAC Device, WATCHMAN FLX Pro Left Atrial Appendage Closure Device | Boston Scientific Corporation | Atrial Fibrillation, Stroke, Bleeding | 07/26 | 01/27 | | |
| Active, not recruiting | N/A | 102 | Europe, US | XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) | Abbott Medical Devices | Coronary Artery Disease | 08/25 | 08/27 | | |
| Recruiting | N/A | 15 | US | AltaValve | 4C Medical Technologies, Inc. | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence | 09/25 | 09/25 | | |
NCT05069558: Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion |
|
|
| Active, not recruiting | N/A | 450 | Europe, Canada, US | Investigational PFO Closure Device, Standard of Care PFO Closure Device | Occlutech International AB | Stroke, Patent Foramen Ovale, PFO | 11/25 | 10/26 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MitraClip™ device implantation, Mitral Valve Repair Surgery | Abbott Medical Devices | Mitral Valve Regurgitation | 04/26 | 04/34 | | |
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. |
|
|
| Recruiting | N/A | 1056 | Europe, Canada, US | Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) | Medtronic Cardiovascular | Mitral Valve Regurgitation | 10/26 | 09/36 | | |
| Active, not recruiting | N/A | 3000 | Europe, Canada, Japan, US, RoW | WATCHMAN FLX LAAC Device, WATCHMAN FLX Left Atrial Appendage Closure Device, Non-Vitamin K Oral Anticoagulant, NOAC | Boston Scientific Corporation | Atrial Fibrillation, Stroke, Bleeding | 12/27 | 12/27 | | |
NCT00573027: Heart Disease of the Small Arteries in Women and Men |
|
|
| Recruiting | N/A | 634 | US | noninvasive tests | Cedars-Sinai Medical Center | Heart Disease | 01/40 | 01/40 | | |
| Daggubati, Ramesh |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
| Recruiting | N/A | 650 | Europe, Canada, Japan, US, RoW | Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) | Medtronic Cardiovascular | Moderate Aortic Valve Stenosis | 02/26 | 12/34 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
| Badhwar, Vinay |
OPTIMAL, NCT05156437: Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis |
|
|
| Enrolling by invitation | 4 | 20 | US | Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline | Vinay Badhwar | Endocarditis | 10/24 | 10/24 | | |
| Recruiting | 3 | 3200 | Europe, Canada, US | Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy | Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center | Atrial Fibrillation, Stroke, Bleeding | 06/25 | 06/25 | | |
| Recruiting | N/A | 150 | US | Focus Groups/Quantitative Survey for Patients, Focus Group/Quantitative Survey for HCPs, Qualitative Focus Group | Northwell Health, West Virginia University, Cedars-Sinai Medical Center, The Cleveland Clinic, University of Kansas Medical Center, Saint Luke's Mid America Heart Institute | Mitral Valve Prolapse | 01/24 | 02/25 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 05/24 | 06/28 | | |
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment |
|
|
| Active, not recruiting | N/A | 150 | US | AtriCure CryoICE & AtriClip LAA Exclusion | AtriCure, Inc. | Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 06/24 | 06/26 | | |
PRIMARY, NCT05051033: Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds |
|
|
| Recruiting | N/A | 450 | Europe, Canada, US | Mitral valve repair, Mitral valve surgery, Transcatheter edge-to-edge repair, TEER | Annetine Gelijns, National Heart, Lung, and Blood Institute (NHLBI) | Mitral Valve Regurgitation | 01/28 | 01/32 | | |
| Rinaldi, Michael J |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
| Recruiting | N/A | 25 | US | CardioMech MVRS | CardioMech AS | Mitral Regurgitation | 12/25 | 12/30 | | |
NCT03735667: ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement |
|
|
| Active, not recruiting | N/A | 1948 | Canada, US | ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL | Boston Scientific Corporation | Aortic Stenosis | 06/24 | 09/34 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 05/24 | 06/28 | | |
| Recruiting | N/A | 50 | Canada, US | Cephea Mitral Valve System | Abbott Medical Devices | Mitral Regurgitation | 03/26 | 03/31 | | |
| Active, not recruiting | N/A | 949 | US | WATCHMAN FLX Pro LAAC Device, Left Atrial Appendage Closure | Boston Scientific Corporation | Atrial Fibrillation, Bleeding, Stroke | 07/24 | 08/25 | | |
| Recruiting | N/A | 15 | US | AltaValve | 4C Medical Technologies, Inc. | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence | 09/25 | 09/25 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MitraClip™ device implantation, Mitral Valve Repair Surgery | Abbott Medical Devices | Mitral Valve Regurgitation | 04/26 | 04/34 | | |
| Ailawadi, Gorav |
| Recruiting | 3 | 3200 | Europe, Canada, US | Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy | Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center | Atrial Fibrillation, Stroke, Bleeding | 06/25 | 06/25 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 05/24 | 06/28 | | |
| Recruiting | N/A | 50 | Canada, US | Cephea Mitral Valve System | Abbott Medical Devices | Mitral Regurgitation | 03/26 | 03/31 | | |
| Active, not recruiting | N/A | 1070 | Europe, US | Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure | 06/24 | 12/29 | | |
| Recruiting | N/A | 10 | US | Transcatheter Tricuspid Valve Replacement, TRiCares Topaz Tricuspid Valve Replacement System | TRiCares | Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases | 10/25 | 10/30 | | |
| Recruiting | N/A | 870 | Canada, US | Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy | Edwards Lifesciences | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease | 12/27 | 12/31 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MitraClip™ device implantation, Mitral Valve Repair Surgery | Abbott Medical Devices | Mitral Valve Regurgitation | 04/26 | 04/34 | | |
| Recruiting | N/A | 842 | Canada, US | CardioGard Embolic Protection Cannula, Standard Aortic Cannula | Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI) | Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease | 04/27 | 04/27 | | |
PRIMARY, NCT05051033: Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds |
|
|
| Recruiting | N/A | 450 | Europe, Canada, US | Mitral valve repair, Mitral valve surgery, Transcatheter edge-to-edge repair, TEER | Annetine Gelijns, National Heart, Lung, and Blood Institute (NHLBI) | Mitral Valve Regurgitation | 01/28 | 01/32 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MITRIS RESILIA Mitral Valve, Model 11400M | Edwards Lifesciences | Mitral Stenosis, Mitral Valve Insufficiency | 01/28 | 12/35 | | |
| Mehmi, Inderjit |
NCT06594991: A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma |
|
|
| Recruiting | 2 | 88 | US | Fianlimab, Cemiplimab, Ipilimumab | Memorial Sloan Kettering Cancer Center, Regeneron Pharmaceuticals | Advanced Melanoma | 09/27 | 09/27 | | |
NCT05428007: Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma |
|
|
| Recruiting | 2 | 69 | US | Sarilumab, REGN88, Ipilimumab Injection, BMS-734016, MDX010, MDX-CTLA4, Nivolumab/Relatlimab, BMS-986213 | NYU Langone Health | Melanoma, Unresectable Melanoma | 06/25 | 12/25 | | |
| Recruiting | 2 | 140 | Canada, US | brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA® | Seagen Inc., Merck Sharp & Dohme LLC | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | 10/25 | 09/26 | | |
NCT04462406: Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial |
|
|
| Recruiting | 2 | 150 | US | Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma | 08/26 | 08/26 | | |
NCT04640246: Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 60 | US, RoW | TBX-3400 | Taiga Biotechnologies, Inc. | Cancer, Tumor, Solid, Refractory Cancer | 01/23 | 04/23 | | |
| Recruiting | 1/2 | 320 | US, RoW | BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta) | BioAtla, Inc. | NSCLC, Melanoma | 12/25 | 06/26 | | |
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors |
|
|
| Terminated | 1/2 | 45 | US, RoW | Modakafusp Alfa, TAK-573, Pembrolizumab | Takeda | Neoplasms, Melanoma | 12/23 | 12/23 | | |
NCT03385486: Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors |
|
|
| Recruiting | 1 | 72 | US | TBX-3400 | Taiga Biotechnologies, Inc. | Stage III Melanoma, Stage IV Melanoma | 02/23 | 12/24 | | |
NCT05004025: Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma |
|
|
| Recruiting | 1 | 10 | US | Novocure Optune, Opdivo, Nivolumab, Yervoy, Ipilimumab | HonorHealth Research Institute, NovoCure Ltd. | Uveal Melanoma | 08/25 | 08/25 | | |
| Alkhouli, Mohamad |
| Completed | N/A | 101 | US | WATCHMAN device implant procedure utilizing ICE probe, WATCHMAN | Mayo Clinic | Left Atrial Appendage Closure With WATCHMAN Device Utilizing an Intra-procedural ICE Probe | 12/23 | 12/23 | | |
| Recruiting | N/A | 25 | Canada, US | MitraClip TMVR and Watchman LAAO | Mayo Clinic | Nonvalvular Atrial Fibrillation, Severe Degenerative Mitral Regurgitation | 01/26 | 01/26 | | |
ICE WATCHMAN, NCT05136417: Study of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion With the Watchman Device |
|
|
| Completed | N/A | 100 | US | intra-procedural intracardiac echocardiography (ICE) probe | Mayo Clinic | Left Atrial Appendage Occlusion | 12/23 | 12/23 | | |
NCT05006443: Staging Classification of Severe Tricuspid Regurgitation Using Novel Cardiac Imaging Techniques |
|
|
| Active, not recruiting | N/A | 75 | US | Cardiac Magnetic Resonance, Cardiac MRI | Mayo Clinic | Tricuspid Regurgitation | 12/23 | 12/24 | | |
| Recruiting | N/A | 150 | US | Sponsor MCG device (CardiAQ) | SB Technology, Inc., Mayo Clinic | Acute Coronary Syndrome | 03/25 | 06/25 | | |
| Recruiting | N/A | 475 | Europe, Canada, US | Amulet™ 2 Left Atrial Appendage (LAA) Occluder | Abbott Medical Devices | Atrial Fibrillation (AF), Stoke | 07/26 | 07/28 | | |
| Sundareswaran, Kartik |
NCT03539458: Feasibility Study of the Tendyne Mitral Valve System in Mitral Annular Calcification |
|
|
| Completed | N/A | 11 | US | Tendyne Mitral Valve System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Annular Calcification, Mitral Annulus Calcification, Cardiovascular Diseases, Valve Heart Disease, Heart Valve Diseases, Heart Valve Calcification, Mitral Valve Disease | 11/19 | 06/24 | | |
| Active, not recruiting | N/A | 1064 | Europe, Canada, Japan, US, RoW | MitraClip G4 System | Abbott Medical Devices, Abbott | Mitral Valve Regurgitation, Mitral Regurgitation | 05/22 | 03/28 | | |
bRIGHT, NCT04483089: An Observational Real-world Study Evaluating Severe Tricuspid Regurgitation Patients Treated with the Abbott TriClip™ Device |
|
|
| Active, not recruiting | N/A | 511 | Europe | Transcatheter heart valve procedure | Abbott Medical Devices | Tricuspid Valve Regurgitation | 12/27 | 01/28 | | |
| Fraser, Neil |
| Completed | 4 | 580 | US | Galcanezumab, LY2951742, Rimegepant, Placebo | Eli Lilly and Company | Migraine, Episodic Migraine | 05/23 | 05/23 | | |
|
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor |
|
|
| Recruiting | 3 | 1250 | Canada, US, RoW | Retatrutide, LY3437943, Semaglutide | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 12/26 | 03/27 | | |
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections |
|
|
| Completed | 3 | 730 | Europe, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar | Eli Lilly and Company, Eli Lilly and Company | Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | 02/24 | 02/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 795 | US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, T2D | 07/24 | 07/24 | | |
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities |
|
|
| Completed | 3 | 751 | US | Tirzepatide, LY3298176, Semaglutide | Eli Lilly and Company | Obesity, Overweight | 11/24 | 11/24 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
